Cabotegravir plus rilpivirine long-acting as HIV-1 maintenance therapy: ATLAS Week 96 results

被引：0
|
作者：
Swindells, S. [1 ]
Lutz, T. [2 ]
Van Zyl, L. [3 ]
Porteiro, N. [4 ]
Benn, P. [5 ]
Huang, J. [6 ]
Harrington, C. [7 ]
Hove, K. [8 ]
Ford, S. [9 ]
Talarico, C. [7 ]
Chounta, V. [5 ]
Crauwels, H. [10 ]
Van Solingen-Ristea, R. [10 ]
Vanveggel, S. [10 ]
Margolis, D. [7 ]
Smith, K. [7 ]
Vandermeulen, K. [10 ]
Spreen, W. [7 ]
机构：
[1] Univ Nebraska Med Ctr, Nebraska Med Ctr, Omaha, NE USA
[2] Infektiologikum, Frankfurt, Germany
[3] Syzygy Clin Res Serv, Pretoria, South Africa
[4] Fdn IDEAA, Buenos Aires, DF, Argentina
[5] ViiV Healthcare, Brentford, England
[6] GlaxoSmithKline, Mississauga, ON, Canada
[7] ViiV Healthcare, Res Triangle Pk, NC USA
[8] GlaxoSmithKline, London, England
[9] GlaxoSmithKline, Res Triangle Pk, NC USA
[10] Janssen Res & Dev, Beerse, Belgium
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P006
引用
收藏
页码：19 / 21
页数：3
相关论文
共 50 条
  • [31] CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING ANTIRETROVIRAL THERAPY ADMINISTERED EVERY 2-MONTHS IS COST EFFECTIVE FOR THE TREATMENT OF HIV-1 IN SPAIN
    Moreno Guillen, S.
    Rivero, A.
    Ventayol, P.
    Falco, V.
    Torralba, M.
    Schroeder, M.
    Neches, V.
    Vallejo-Aparicio, L. A.
    Mackenzie, I.
    Turner, M.
    Harrison, C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S122 - S122
  • [32] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
    Moreno, Santiago
    Rivero, Antonio
    Ventayol, Pere
    Falco, Vicenc
    Torralba, Miguel
    Schroeder, Melanie
    Neches, Victoria
    Vallejo-Aparicio, Laura Amanda
    Mackenzie, Isaac
    Turner, Matthew
    Harrison, Cale
    [J]. INFECTIOUS DISEASES AND THERAPY, 2023, 12 (08) : 2039 - 2055
  • [33] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
    Santiago Moreno
    Antonio Rivero
    Pere Ventayol
    Vicenç Falcó
    Miguel Torralba
    Melanie Schroeder
    Victoria Neches
    Laura Amanda Vallejo-Aparicio
    Isaac Mackenzie
    Matthew Turner
    Cale Harrison
    [J]. Infectious Diseases and Therapy, 2023, 12 : 2039 - 2055
  • [34] Cost-utility analysis of long-acting cabotegravir plus rilpivirine for the treatment of HIV infection in the United Kingdom
    Parker, B.
    Chounta, V.
    Gait, C.
    Hayward, O.
    Hunjan, M.
    Schroeder, M.
    Jacob, I.
    Van de Velde, N.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 37 - 37
  • [35] Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection (ITT-E population)
    Orkin, C.
    D'Amico, R.
    Bernal Morell, E.
    Tan, D. H. S.
    Katner, H.
    Singh, Y.
    Stellbrink, H-J
    Belonosova, E.
    DeMoor, R.
    Griffith, S.
    Thiagarajah, S.
    Van Solingen-Ristea, R.
    Ford, S. L.
    Crauwels, H.
    Patel, P.
    Cutrell, A.
    Smith, K. Y.
    Vandermeulen, K.
    St Clair, M.
    Spreen, W. R.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 22 - 22
  • [36] Uptake and discontinuation of the long-acting duo in the Swiss HIV Cohort Study: Preliminary analysis on cabotegravir plus rilpivirine
    Ramirez, J. J. Duran
    Kusejko, K.
    Metzner, K. J.
    Huber, M.
    Martin, Y.
    Stockle, M.
    Calmy, A.
    Decosterd, L. A.
    Cavassini, M.
    Bernasconi, E.
    Schmid, P.
    Gunthard, H. F.
    Braun, D. L.
    [J]. HIV MEDICINE, 2023, 24 : 79 - 81
  • [37] Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
    Mills, Anthony
    Richmond, Gary J.
    Newman, Cheryl
    Osiyemi, Olayemi
    Cade, Jerry
    Brinson, Cynthia
    De Vente, Jerome
    Margolis, David A.
    Sutton, Kenneth C.
    Wilches, Viviana
    Hatch, Sarah
    Roberts, Jeremy
    McCoig, Cynthia
    Garris, Cindy
    Vandermeulen, Kati
    Spreen, William R.
    [J]. AIDS, 2022, 36 (02) : 195 - 203
  • [38] Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
    Orkin, Chloe
    Morell, Enrique Bernal
    Tan, Darrell H. S.
    Katner, Harold
    Stellbrink, Hans-Juergen
    Belonosova, Elena
    DeMoor, Rebecca
    Griffith, Sandy
    Thiagarajah, Shanker
    Van Solingen-Ristea, Rodica
    Ford, Susan L.
    Crauwels, Herta
    Patel, Parul
    Cutrell, Amy
    Smith, Kimberly Y.
    Vandermeulen, Kati
    Birmingham, Eileen
    St Clair, Marty
    Spreen, William R.
    D'Amico, Ronald
    [J]. LANCET HIV, 2021, 8 (11): : E668 - E678
  • [39] Use of long-acting cabotegravir plus rilpivirine during hemodialysis and solid organ transplantation
    Rezzonico, Leonardo F.
    Baldassari, Luca
    Peracchi, Francesco
    Merli, Marco
    Puoti, Massimo
    Rossotti, Roberto
    [J]. AIDS, 2023, 37 (09) : 1491 - 1493
  • [40] Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European locations (CARISEL)
    Jonsson-Oldenbuettel, C.
    Ghosn, J.
    Sierra, J. Olalla
    van der Valk, M.
    Lutz, T.
    Belkhir, L.
    van Welzen, B. J.
    Hove, K.
    Ait-Khaled, M.
    DeMoor, R.
    Bontempo, G.
    Latham, C. L.
    Ngenzi, B.
    Okoli, C.
    Gutner, C. A.
    Iyer, S.
    Gill, M.
    Czarnogorski, M.
    D'Amico, R.
    van Wyk, J.
    [J]. HIV MEDICINE, 2023, 24 : 193 - 195
12345